Coming Soon: Bivalent Booster Dose for Select COVID-19 Vaccines
Updated November 16, 2022
Originally published September 14, 2022
Update: On November 16, 2022, Medi-Cal announced that claims for the administration of the Bivalent booster vaccination for the Pfizer-BioNTech COVID-19 vaccine, in individuals 12 years of age or older, and the Moderna COVID-19 vaccine, in individuals 18 years of age and older, can now be processed. For the most current direction regarding billing guidelines for the administration of the Bivalent booster dose, refer to the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine web pages.
Effective for dates of service on or after August 31, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUA) for a Bivalent booster formulation for the Pfizer COVID-19 vaccine and Moderna COVID-19 vaccine, to be administered at least two months after either primary vaccination or booster dose with any authorized/approved monovalent COVID-19 vaccine, to the following groups:
Pfizer-BioNTech COVID-19 Vaccine
Individuals 12 years of age or older as a single booster dose.
Moderna COVID-19 Vaccine
Individuals 18 years of age and older as a single booster dose.
For the most current information regarding Medi-Cal’s COVID-19 Response, see the COVID-19 Medi-Cal Response page on the Medi-Cal Providers website.